Literature DB >> 33758330

A novel target for combination immunotherapy in pancreatic cancer: IL-1β mediates immunosuppression in the tumour microenvironment.

Rafael Winograd1,2, Diane M Simeone2,3,4, Dafna Bar-Sagi5.   

Abstract

Immune checkpoint blockade (ICB) has demonstrated efficacy in multiple cancers, offering the potential of long-term disease control not achievable with cytotoxic or targeted therapies. However, the field has not yet achieved the crucial next steps - the expansion of the response rate and achievement of clinical efficacy in so-called "cold tumours". Mechanistic studies of tumour-type specific immunosuppressive pathways can reveal underlying biological hurdles to immunotherapy and offer new therapeutic insights. Our finding that tumour-derived IL-1β mediates immunosuppression in pancreatic cancer has precipitated a new clinical trial.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33758330      PMCID： PMC8144204          DOI： 10.1038/s41416-021-01303-2

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  4 in total

1.  Pancreatic Ductal Adenocarcinoma (PDAC) circulating tumor cells influence myeloid cell differentiation to support their survival and immunoresistance in portal vein circulation.

Authors:  Juan Pablo Arnoletti; Joseph Reza; Armando Rosales; Alberto Monreal; Na'im Fanaian; Suzanne Whisner; Milan Srivastava; Julia Rivera-Otero; Gongxin Yu; Otto Phanstiel Iv; Deborah A Altomare; Quang Tran; Sally A Litherland
Journal:  PLoS One       Date:  2022-03-22       Impact factor: 3.240

2.  First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours.

Authors:  Debbie Robbrecht; Christiane Jungels; Morten Mau Sorensen; Iben Spanggaard; Ferry Eskens; Signe Ø Fretland; Tormod Kyrre Guren; Philippe Aftimos; David Liberg; Christer Svedman; Lars Thorsson; Neeltje Steeghs; Ahmad Awada
Journal:  Br J Cancer       Date:  2021-12-13       Impact factor: 9.075

3.  Single-cell transcriptomics reveals shared immunosuppressive landscapes of mouse and human neuroblastoma.

Authors:  Ana Costa; Cécile Thirant; Amira Kramdi; Cécile Pierre-Eugène; Caroline Louis-Brennetot; Orphée Blanchard; Didier Surdez; Nadege Gruel; Eve Lapouble; Gaëlle Pierron; Deborah Sitbon; Hervé Brisse; Arnaud Gauthier; Paul Fréneaux; Mylène Bohec; Virginie Raynal; Sylvain Baulande; Renaud Leclere; Gabriel Champenois; Andre Nicolas; Didier Meseure; Angela Bellini; Aurelien Marabelle; Birgit Geoerger; Fatima Mechta-Grigoriou; Gudrun Schleiermacher; Laurie Menger; Olivier Delattre; Isabelle Janoueix-Lerosey
Journal:  J Immunother Cancer       Date:  2022-08       Impact factor: 12.469

4.  TiSe2-mediated sonodynamic and checkpoint blockade combined immunotherapy in hypoxic pancreatic cancer.

Authors:  Libin Chen; Wang Xue; Jing Cao; Shengmin Zhang; Yiqing Zeng; Ling Ma; Xuechen Qian; Qing Wen; Yurong Hong; Zhan Shi; Youfeng Xu
Journal:  J Nanobiotechnology       Date:  2022-10-15       Impact factor: 9.429
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.